Under the agreement, Maternova will have exclusive distribution rights across Latin America and non-exclusive rights in the United States for MedMira's Reveal, Multiplo and Miriad brands that are aimed at reducing HIV, hepatitis, syphilis and other infectious and sexually transmitted diseases.
The new partnership increases Maternova's product lines by offering additional unique, quality products, including the Multiplo TP/HIV rapid test that delivers 100% sensitivity in identifying co-infections and is helping to reduce mother-to-child transmission of syphilis and HIV.
In addition, the Reveal G4 HIV rapid test provides the highest sensitivity and specificity as outlined in recent studies conducted by the CDC.
All products are exclusively produced in Canada in an FDA- and MDSAP-certified manufacturing facility and conform to all required standards.
Maternova is a sponsor of the Action on Disaster Relief (ADR2023) event being held in Panama City, Panama from February 22-23.
MedMira's products will be available to review at Maternova's exhibit booth 5. Maternova CEO Prakash Veenam will also chair the Regional International Support & Coordination panel on February 23 at 10: 50 a.m. EST.
He will discuss how international organizations can pool their resources to reduce mortality rates caused by natural disasters, including timely medical support, humanitarian disaster relief operations, and coordinating strategic relief activities.
Maternova is a health solutions company and the leading global marketplace for lifesaving, evidence-based medical innovations in maternal, newborn and reproductive health.
Founded in 2009, Maternova launched the first-of-its-kind e-commerce marketplace for distributors, governments and humanitarian organizations to research, source and fulfill orders of trusted and rigorously tested medical devices, diagnostics and nutritional products that enhance care.
Since 2015, Maternova has impacted the lives of more than 1.2 m mothers and babies around the world.
MedMira is a leading developer and manufacturer of Rapid Vertical Flow Technology diagnostics.
The company's tests provide hospitals, labs, clinics and individuals with instant disease diagnosis, such as HIV, syphilis, hepatitis and SARS-CoV-2, in just three easy steps.
The company's tests are sold globally under the REVEAL, REVEALCOVID-19, Multiplo and Miriad brands.
Based on its patented Rapid Vertical Flow Technology, MedMira's rapid HIV test is the only one in the world to achieve regulatory approvals in Canada, the United States, China and the European Union. MedMira's corporate offices and manufacturing facilities are located in Halifax, Nova Scotia, Canada.
Quanterix partners with leading health networks for Alzheimer's diagnosis advancements
Precision BioSciences reports FDA pre-IND feedback for PBGENE-HBV
VBI to sell manufacturing capabilities and enter new license agreement with Brii Biosciences
Ondine Biomedical's Steriwave shows promise in nasal pathogen reduction
BioSenic expands patent coverage for ATO therapeutic platform
PacBio unveils Nanobind PanDNA kit for enhanced DNA extraction solutions
Sequentify receives funding from Israel Innovation Authority
INOVIO plans BLA submission for INO-3107 as RRP treatment
ImmunityBio secures USD320m investment from Oberland Capital
Poolbeg Pharma prioritises promising RSV drug candidates identified through AI-led analysis
GHIT fund invests JPY500m in antimalarial drug clinical trial
AstraZeneca agrees acquisition of Icosavax
Versameb names new chairman of the board
Kling Bio appoints Dr Stefano Gullà as chief scientific officer